Canopy Growth Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Canopy Growth wird ein jährliches Gewinn- und Umsatzwachstum von 54.9% bzw. 11.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 56.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -221.8% betragen.

Wichtige Informationen

46.4%

Wachstumsrate der Gewinne

63.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.8%
Wachstumsrate der Einnahmen	6.5%
Zukünftige Eigenkapitalrendite	-22.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	01 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges

Oct 05

Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High

Aug 27

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Feb 06

Canopy Growth: Further Implosion Is Now A Matter Of When Not If

Jan 29

Avoid Canopy Growth After Failed Equity Sale

Jan 14

Canopy Growth (Nasdaq:CGC): Further Dilution Seems Inevitable

Oct 13

Canopy Growth: Getting High

Oct 07

Quick Takes: Tesla, Twitter, Carvana & More

Oct 06

Canopy Growth to sell Canadian retail operations, including Tokyo Smoke stores

Sep 27

Canopy Growth: BioSteel Sizzles, Everything Else Fizzles

Aug 30

What Is Canopy Growth's Stock Outlook After Earnings Miss?

Aug 23

Canopy Growth leads cannabis rally as Senator backs compromise legislation

Aug 08

Canopy gains 12% to lead Canadian cannabis rally as former Aphria legal chief joins

Aug 02

Canopy Growth: Constellation's Investment Goes Up In Smoke

Jul 18

Canopy Growth: Bankruptcy Risks Are Growing Like A Weed

Jun 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CGC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	338	-80	-59	-59	3
3/31/2026	309	-106	-78	-91	8
3/31/2025	286	-188	-130	-108	11
6/30/2024	287	-602	-191	-185	N/A
3/31/2024	297	-484	-286	-282	N/A
12/31/2023	293	-984	-407	-400	N/A
9/30/2023	299	-976	-520	-511	N/A
6/30/2023	317	-1,025	-576	-566	N/A
3/31/2023	333	-3,079	-568	-558	N/A
12/31/2022	367	-3,051	-559	-544	N/A
9/30/2022	423	-2,938	-583	-568	N/A
6/30/2022	466	-2,766	-550	-521	N/A
3/31/2022	476	-255	-594	-546	N/A
12/31/2021	557	-428	-587	-517	N/A
9/30/2021	569	-1,223	-552	-437	N/A
6/30/2021	572	-1,244	-644	-513	N/A
3/31/2021	547	-1,745	-622	-466	N/A
12/31/2020	506	-2,348	-803	-579	N/A
9/30/2020	477	-1,535	-1,033	-681	N/A
6/30/2020	419	-1,244	-1,282	-733	N/A
3/31/2020	399	-1,321	-1,495	-773	N/A
12/31/2019	385	-415	-1,610	-802	N/A
9/30/2019	344	-256	-1,578	-709	N/A
6/30/2019	291	-832	-1,408	-626	N/A
3/31/2019	226	-736	-1,254	-535	N/A
12/31/2018	155	-398	-958	-332	N/A
9/30/2018	94	-464	-709	-257	N/A
6/30/2018	88	-148	-462	-137	N/A
3/31/2018	78	-67	N/A	-82	N/A
12/31/2017	70	-21	N/A	-60	N/A
9/30/2017	58	-19	N/A	-41	N/A
6/30/2017	49	-13	N/A	-36	N/A
3/31/2017	40	-8	N/A	-27	N/A
12/31/2016	30	-1	N/A	-14	N/A
9/30/2016	24	-7	N/A	-15	N/A
6/30/2016	18	-8	N/A	-14	N/A
3/31/2016	13	-3	N/A	-14	N/A
12/31/2015	8	0	N/A	-14	N/A
9/30/2015	6	1	N/A	-12	N/A
6/30/2015	3	-5	N/A	-10	N/A
3/31/2015	2	-7	N/A	-9	N/A
12/31/2014	1	-9	N/A	-10	N/A
9/30/2014	1	-7	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CGCDie Einnahmen des Unternehmens (7.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: CGCDie Einnahmen des Unternehmens (11.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CGC wird voraussichtlich in 3 Jahren unrentabel sein.

Canopy Growth Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges

Insider recently sold US$103k worth of stock

Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High

David Klein Announces to Retire as CEO of Canopy Growth Corporation

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Canopy Growth Corporation to Report Q2, 2025 Results on Nov 12, 2024

Canopy Growth Corporation to Report Q1, 2025 Results on Aug 09, 2024

Canopy Growth Corporation, Annual General Meeting, Sep 24, 2024

Now 22% undervalued after recent price drop

Now 20% overvalued

Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)

Canopy Growth Corporation has filed a Follow-on Equity Offering in the amount of $250 million.

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Canopy Growth: Another Ugly Cannabis Report

Canopy Growth Corporation to Report Q4, 2024 Results on May 30, 2024

New major risk - Shareholder dilution

Canopy Growth Corporation (TSX:WEED) exercised its option to acquire Wana Brands for $300 million.

Canopy Growth Set For U.S. Cannabis Markets

Less than half of directors are independent

Canopy Growth Corporation Announces Board and Committee Changes

New major risk - Share price stability

Canopy Growth Is Climbing, But It Won't Last

Canopy Growth Launches New Pre-Rolls from 7Acres and Hiway

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Canopy Growth Corporation Announces Board Changes

New major risk - Revenue and earnings growth

Bioriginal Food & Science Corporation acquired KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED).

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Canopy Growth: Further Implosion Is Now A Matter Of When Not If

Canopy Growth Corporation Announces the Introduction of New Product Offerings Across the Company's Adult Use and Medical Cannabis Portfolio

Canopy Growth Corporation announced that it expects to receive $35.000008 million in funding

Avoid Canopy Growth After Failed Equity Sale

Canopy Growth Corporation to Report Q3, 2024 Results on Feb 09, 2024

Canopy Growth Corporation announced that it expects to receive $30 million in funding

Inspirit Management Ltd acquired This Works Products Limited from Canopy Growth Corporation (TSX:WEED) for £9.3 million.

Canopy Growth Corporation Partners with Marquee Brands Partners and Martha Stewart CBD to Unveil New Line of Need-Based CBD Gummies

New minor risk - Insider selling

Canopy Growth Corporation Announces the Addition of Four New Flower Product Offerings from Iconic Brands 7ACRES and Tweed

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Canopy Growth Corporation announced that it expects to receive $24.99312 million in funding

Canopy Growth Corporation announced that it expects to receive $24.99312 million in funding

Canopy Growth Corporation Announces Addition of Five New Pre-Roll Flower Product Offerings from Iconic Brands Tweed, 7ACRES, and for the First Time, from Spectrum Therapeutics

Canopy Growth Corporation Announces Executive Changes

Canopy Growth Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Canopy Growth Corporation, Annual General Meeting, Sep 25, 2023

Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuit on Behalf of the Investors in Canopy Growth Corporation Who Suffered Losses from Purchasing or Otherwise Acquiring Canopy Securities Between June 1, 2021 and May 10, 2023

An unknown buyer acquired a Facility in Modesto, CA from Canopy Growth Corporation (TSX:WEED).

Canopy Growth Corporation to Report Q4, 2023 Results on Jun 22, 2023

Canopy Growth Corporation announced delayed amended 10-K filing

Canopy Growth Corporation announced delayed annual 10-K filing

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Canopy Growth Corporation

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

420 Investments Ltd. acquired Five Retail Locations in Alberta from Canopy Growth Corporation (TSX:WEED).

Canopy Growth Corporation Announces Termination of Julious Grant as Chief Commercial Officer, Effective December 16, 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Canopy Growth Corporation (TSX:WEED) acquired Manufacturing facility in USA.

Canopy Growth Corporation Announces Extension of Its Ace Valley Brand Portfolio with the Launch of Lust Cherry Rose and Thrust Watermelon Goji

Canopy Growth (Nasdaq:CGC): Further Dilution Seems Inevitable

Canopy Growth: Getting High

Quick Takes: Tesla, Twitter, Carvana & More

420 Investments Ltd. agreed to acquire Five Retail Locations in Alberta from Canopy Growth Corporation (TSX:WEED).

Canopy Growth to sell Canadian retail operations, including Tokyo Smoke stores

Canopy Growth: BioSteel Sizzles, Everything Else Fizzles

What Is Canopy Growth's Stock Outlook After Earnings Miss?

Limited-Edition Pumpkin Spice CBD Wellness Gummies™ Arrive Just in Time for Fall As Martha Stewart CBD Expands Portfolio

Canopy Growth leads cannabis rally as Senator backs compromise legislation

Canopy Growth Corporation Appoints Christelle Gedeon as Chief Legal Officer

Canopy gains 12% to lead Canadian cannabis rally as former Aphria legal chief joins

Canopy Growth Corporation Announces New Premium Flower Line-Up

Canopy Growth: Constellation's Investment Goes Up In Smoke

Canopy Growth Corporation Celebrates Summer with New 'Just Hits Different' Beverage Campaign

Canopy Growth: Bankruptcy Risks Are Growing Like A Weed

Canopy Growth Corporation to Report Q3, 2023 Results on Feb 09, 2023